MedAd­vi­sor-Zuel­lig Asia JV

Pharmacy Daily - - News -

ASX LISTED dig­i­tal med­i­ca­tion man­age­ment com­pany MedAd­vi­sor signed a Heads of Agree­ment to form a 50:50 joint ven­ture (JV) with Zuel­lig Pharma Hold­ings, one of the largest health ser­vices groups in Asia (PD break­ing news).

The new ven­ture will be based in Sin­ga­pore with cross-li­cens­ing agree­ments around MedAd­vi­sor’s in­tel­lec­tual prop­erty while re­tain­ing own­er­ship rights for the plat­form in­clud­ing any cus­tomi­sa­tions ac­com­mo­dat­ing spe­cific coun­tries.

With close to 100 years of op­er­at­ing his­tory, Zuel­lig Pharma’s US$12 bil­lion busi­ness pro­vides health­care ser­vices to over 350,000 med­i­cal fa­cil­i­ties - in­clud­ing phar­ma­cies, med­i­cal clin­ics and hospi­tals - across Asia, while the firm also works with over 1,000 cor­po­rate clients, in­clud­ing the top 10 pharma com­pa­nies in the world.

Zuel­lig Pharma says it puts em­pha­sis on pro­vid­ing phar­macy and med­i­cal clinic cus­tomers with state-of-the-art dig­i­tal cus­tomer ser­vice ca­pa­bil­i­ties to help cater to the grow­ing con­ve­nience and ser­vice ex­pec­ta­tions of pa­tients, and sees MedAd­vi­sor as a suit­able part­ner with the abil­ity to sup­port an ex­ten­sive num­ber of its cus­tomers in the re­gion.

Zuel­lig Pharma plans to mar­ket the joint ven­ture’s of­fer­ing to its ex­ten­sive net­work of phar­ma­cies, med­i­cal clin­ics and phar­ma­ceu­ti­cal man­u­fac­tur­ers, ini­tially fo­cussing on the Philip­pines, with about 27,000 phar­ma­cies, and South Korea where there are an es­ti­mated 21,000 phar­ma­cies.

A roll­out in 2019/20 will be fol­lowed by launches in ad­di­tional Asian mar­kets, the com­pa­nies said.

MedAd­vi­sor says the ad­dress­able pop­u­la­tion in the de­fined mar­kets ex­ceeds 560m peo­ple while the phar­ma­ceu­ti­cal spend is es­ti­mated to be US$69b.

EBOS holds a 14.1% strate­gic stake in MedAd­vi­sor.

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.